Source: Annual Congress 2011 - New treatments for airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Laviolette, I. Pavord, N. Thomson, R. Niven, G. Cox, P. Corris, K. Fan-Chung (Québec, Hamilton, Canada; Leicester, Glasgow, Manchester, Newcastle-upon-Tyne, London, United Kingdom). Safety of bronchial thermoplasty out to 5 years in patients with severe refractory asthma: Research in severe asthma (RISA) trial. Eur Respir J 2011; 38: Suppl. 55, 3422

Member's Comments

No comment yet.

Related content which might interest you: Long-term (5 year) safety of bronchial thermoplasty in patients with moderate to severe asthma: Asthma Intervention Research (AIR) Trial Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Efficacy of bronchial thermoplasty (BT) in patients with severe asthma: the AIR2 trial Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009 Reslizumab (RES) in asthma patients (pts) with severe eosinophilic asthma stratified by GINA asthma steps 4 and 5: Analysis of two phase 3, placebo (PBO)-controlled trials Source: International Congress 2016 – Asthma management Year: 2016 Cost-effectiveness of bronchial thermoplasty (BT) treatment relative to no BT treatment option for patients with severe asthma Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Clinical response of severe asthma patients following Bronchial Thermoplasty. Source: International Congress 2017 – To freeze or heat? Year: 2017 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Cost-effectiveness of omalizumab in patients with severe persistent allergic (IgE-mediated) asthma: adaptation of INNOVATE and ETOPA data to the Netherlands Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007 Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Cost effectiveness of bronchial thermoplasty for treatment of severe asthma patients in spain Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients? Year: 2017 Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013 Indirect comparison of bronchial thermoplasty (BT) versus omalizumab (OM) for severe uncontrolled asthma Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Efficacy of omalizumab in patients with moderate-to-severe allergic asthma that is poorly controlled on GINA (1998) treatment step 3 or 4 Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Safety of tiotropium Respimat® add-on therapy in patients aged 6-17 years with symptomatic asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Asthma control and exacerbation rate with omalizumab in Italian patients with severe allergic asthma: PROXIMA study Source: International Congress 2017 – Asthma management Year: 2017 Safety of tiotropium in pre-school children with symptomatic persistent asthma Source: International Congress 2016 – Paediatric asthma: lessons learned from studies with large sample sizes and multi-centre drug studies Year: 2016 Bronchial thermoplasty in patients with very severe asthma: Safety and clinical outcomes Source: International Congress 2016 – Airway stenting and ablation Year: 2016 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Clinical experience with montelukast plus ICS vs. only ICS in non-asthmatic eosinophilic bronchitis (NAEB) in Indian patients Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016